Cathie Wood Buys Into a Biotech With a Covid Connection

Published by
The Street

By Dan Weil A biotech that’s caught asset manager Cathie Wood’s attention recently received FDA emergency authorization for a test of Covid antibodies. Star investor Cathie Wood, chief executive of Ark Investment Management, has recently built a stake in a biotechnology company that earlier this month received a dose of good news. The stock is Adaptive Biotechnologies (ADPT) – Get Adaptive Biotechnologies Corp. Report. The Food and Drug Administration has granted emergency-use authorization for a new test developed by the Seattle company to find prior Covid infections. The new test differs fro…

Read More

See also  Reminder: Chrome’s “Incognito” Mode Doesn’t Really Protect Your Privacy

Leave a Reply